DUBLIN--(BUSINESS WIRE)--
ICON plc, (NASDAQ:ICLR) (ISIN:IE0005711209), a global provider of
outsourced development services to the pharmaceutical, biotechnology and
medical device industries, and Proteome Sciences (AIM:PRM) a leading
provider of protein biomarker discovery, validation, and assay
development services, today announced the formation of a strategic
alliance to provide pharmaceutical companies with an expanded biomarker
solution to allow earlier assessments in the development of new
medicines.
Through the alliance with Proteome's PS Biomarker Services™, ICON is
strengthening its current biomarker solution to include an integrated
suite of labeling, separation and mass spectrometry technologies for
protein and peptide profiling in complex biological materials.
ICON and Proteome Sciences are already engaged in their first joint
project which is the development of a mass spectrometry assay for a key
biomarker for an international pharmaceutical development company.
Commenting on the initiation of this project, John Allinson, VP
Biomarker Lab Services, ICON Development Solutions stated: "We are
extremely pleased to be entering this long-term partnership with
Proteome Sciences which allows us to offer our clients access to state
of the art protein and peptide profiling and rapid development of mass
spectrometry assays through PS Biomarker Services™. This complements
ICON's extensive portfolio of biomarker development and analysis
services to help sponsors identify, implement and interpret the right
biomarkers to inform their pre-clinical and clinical drug development."
Dr. Ian Pike, Proteome's Chief Operating Officer added: "We are
delighted to be partnering with the team at ICON Development Solutions
to provide their clients with a complete biomarker solution, including
PS Biomarker Discovery Services™ as part of wider clinical development
programs. The unique power of our proprietary technology platforms to
identify and validate key protein biomarkers of disease and response to
treatment is clearly being recognized and used by the pharmaceutical
industry.
Notes to Editors:
About ICON plc
ICON plc is a global provider of outsourced development services to the
pharmaceutical, biotechnology and medical device industries. The Company
specialises in the strategic development, management and analysis of
programmes that support clinical development - from compound selection
to Phase I-IV clinical studies. ICON currently has around 7,700
employees, operating from 71 offices in 39 countries. For more
information visit www.iconplc.com.
About Proteome Sciences
Proteome Sciences is a global leader in applied proteomics and uses high
sensitivity proprietary technologies for protein biomarker discovery,
validation and assay development. The Company's own research has
discovered a large number of novel protein biomarkers in key human
diseases and is focused mainly in neurological/neurodegenerative
conditions and in cancer. It has discovered and patented blood
biomarkers, including Alzheimer's disease, stroke, brain damage and lung
cancer for diagnostic and treatment applications. These biomarkers are
available for outlicensing. The first blood test for lung cancer using
Proteome Sciences' biomarkers was launched in the USA in 2009 and
received Medicare reimbursement in 2010. Its PS Biomarker Services
provides ISO 9001: 2008 accredited facilities in Frankfurt, Germany,
using proprietary isobaric and isotopic Tandem Mass Tags® (TMT®)
to discover protein biomarkers, and reference materials combined with
isotope dilution mass spectrometry. Highly multiplexed assays can be
developed rapidly and are suitable for screening hundreds of candidate
biomarkers in validation studies. Assays for validated biomarkers can be
transferred for immunoassay development. Proteome Sciences, based in
Cobham, UK, has facilities in London and Frankfurt and delivers
outsourced proteomics services and proprietary biomarkers to
pharmaceutical, biotechnology and diagnostics companies. Visit http://www.proteomics.com.
ICON/ICLR-G
ICON plc
Emily Brand
Corporate Communications Manager
+353-1-2912665
Emily.brand@iconplc.com
or
Proteome
Sciences plc
Dr. Ian Pike, Chief Operating Officer
Tel:
+44 (0)1932 865065
ian.pike@proteomics.com
or
Nominated
Adviser - Singer Capital Markets Limited
Shaun Dobson / Claes
Spång
Tel: +44 (0)20 3205 7500
or
IKON Associates
Adrian
Shaw
Tel: +44 (0)1483 271291
Mobile: +44 (0)7979 900733
Email:
adrian@ikonassociates.com
or
Redleaf
Communications Limited
Anna Dunkin / Lucy Salaman
Tel: +44
(0)20 7566 6700
Email: proteome@redleafpr.com
Source: ICON plc
News Provided by Acquire Media
